Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04752813 · ClinicalTrials.gov registry record · Phase 2
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
A Phase 2 study of Glioblastoma and Glioblastoma Multiforme, sponsored by BPGbio.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 11
- Study locations
NCT04752813 is a Phase 2 study of Glioblastoma and Glioblastoma Multiforme that is active but no longer recruiting, run by BPGbio. The registered enrollment target is 50 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (54% lower). The trial reports 11 study locations across 6 states.
The verdict
NCT04752813, a Phase 2 study of Glioblastoma and Glioblastoma Multiforme, is active but no longer recruiting, sponsored by BPGbio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
Conditions Studied
Interventions
- RADIATION Radiation
- DRUG Temozolomide (TMZ)
- DRUG BPM31510
- OTHER Vitamin K1
Study Locations (11)
California
- Cedars-Sinai Medical Center - Los Angeles
- Stanford University Cancer Center - Palo Alto
- Sansum Clinic - Santa Barbara
Virginia
- Virginia Cancer Specialists - Fairfax
- Inova - Fairfax
- Virginia Oncology Associates - Norfolk
Texas
- Texas Oncology - Austin
- UT Health San Antonio Mays Cancer Center - San Antonio
Massachusetts
- Dana Farber Cancer Institute - Boston
New Jersey
- Valley Health - Ridgewood
New York
- Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-08-22 |
| Est. Completion | 2030-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04752813
The ClinicalTrials.gov registry entry for NCT04752813 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (54% lower). The listed sponsor is BPGbio, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which Radiation is the first listed.
NCT04752813 reports 11 study locations spanning 6 distinct geographic areas - top geographies include California, Virginia, Texas.
Frequently Asked Questions
What is clinical trial NCT04752813 about?
NCT04752813 is a clinical study titled "A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)". This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
What is the current status of trial NCT04752813?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-08-22. Estimated completion is 2030-08-26.
What conditions does trial NCT04752813 study?
This clinical trial studies the following conditions: Glioblastoma, Glioblastoma Multiforme.
What interventions are being tested in trial NCT04752813?
The interventions under investigation include: Radiation (RADIATION), Temozolomide (TMZ) (DRUG), BPM31510 (DRUG), Vitamin K1 (OTHER).
Who is sponsoring clinical trial NCT04752813?
This trial is sponsored by BPGbio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04752813 being conducted?
This trial has 11 study locations across California, Massachusetts, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.